Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 24% Improvement Relative Risk Progression -7% Case -11% c19early.org/e Son et al. Aspirin for COVID-19 Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? PSM retrospective 11,475 patients in South Korea Lower mortality with aspirin (not stat. sig., p=0.52) Son et al., Medicine, doi:10.1097/MD.0000000000026670 Favors aspirin Favors control
Effect of aspirin on coronavirus disease 2019
Son et al., Medicine, doi:10.1097/MD.0000000000026670
Son et al., Effect of aspirin on coronavirus disease 2019, Medicine, doi:10.1097/MD.0000000000026670
Jul 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
PSM retrospective case control study in South Korea, showing a trend towards lower mortality, but no significant differences with aspirin use.
risk of death, 24.0% lower, OR 0.76, p = 0.52, treatment 37 of 128 (28.9%) cases, 31 of 128 (24.2%) controls, adjusted per study, case control OR, group 1, model 2 (most data in group and adjustments), multivariable.
risk of progression, 7.0% higher, OR 1.07, p = 0.80, treatment 77 of 339 (22.7%) cases, 58 of 339 (17.1%) controls, adjusted per study, case control OR, complications, group 1, model 2 (most data in group and adjustments), multivariable.
risk of case, 11.0% higher, OR 1.11, p = 0.21, treatment 313 of 3,825 (8.2%) cases, 617 of 7,650 (8.1%) controls, adjusted per study, case control OR, group 1, PSM 1, model 2 (most data in group and adjustments), multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Son et al., 30 Jul 2021, retrospective, propensity score matching, South Korea, peer-reviewed, 6 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: Medicine ® Observational Study OPEN Effect of aspirin on coronavirus disease 2019 A nationwide case-control study in South Korea Minkook Son, MDa, Myung-giun Noh, MDa, Jeong Hoon Lee, PhDb, Jeongkuk Seo, MDc, ∗ Hansoo Park, MD, PhDa, Sung Yang, PhDa,d, Abstract Several studies reported that aspirin can potentially help prevent infection and serious complications of coronavirus disease (COVID19), but no study has elucidated a definitive association between aspirin and COVID-19. This study aims to investigate the association between aspirin and COVID-19. This case-control study used demographic, clinical, and health screening laboratory test data collected from the National Health Insurance Service database. Patients who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection until June 4, 2020, were matched with control patients using propensity score matching according to their SARS-CoV-2 status, the composite of complications, and death. The composite of complications included intensive care unit admission, use of vasopressors, high-flow oxygen therapy, renal replacement therapy, extracorporeal membrane oxygenation, and death. Exposure to aspirin was defined as having a prescription for aspirin for more than 14 days, including the index date. After matching, multivariableadjusted conditional logistic regression analysis was performed. To confirm the robustness of this study, we used 2 study groups, 3 propensity score matching methods, and 3 models for conditional logistic regression analyses. The crude odds ratio and 95% confidence interval for SARS-CoV-2 infection between the groups without and with exposure to aspirin were 1.21 (1.04–1.41), but the adjusted odds ratios (95% confidence interval) were not significant. There was no association between aspirin exposure and COVID-19 status. Multiple statistical analyses, including subgroup analysis, revealed consistent results. Furthermore, the results of analysis for complications and death were not significant. Aspirin exposure was not associated with COVID-19-related complications and mortality in COVID-19 patients. In this nationwide population-based case-control study, aspirin use was not associated with SARS-CoV-2 infection or related complications. With several ongoing randomized controlled trials of aspirin in COVID-19 patients, more studies would be able to confirm the effectiveness of aspirin in COVID-19. Abbreviations: CCI = Charlson Comorbidity Index, CI = confidence interval, COVID-19 = coronavirus disease, KCDC = Korea Centers for Disease Control and Prevention, NHIS = National Health Insurance Service, NSAIDs = nonsteroidal anti-inflammatory drugs, OR = odds ratio, PSM = propensity score matching, SMD = standardized mean difference, WHO = World Health Organization. Keywords: aspirin, COVID-19, infections, Republic of Korea Editor: Bruno M. Carneiro. MS and MN contributed equally to this work. This work was supported by the National Research Foundation of Korea (NRF) grant, funded by the Korea government (MSIT) (No. 2020R1A5A8018367 and 2021R1A2C3008169). The funders had no role in the study design, data collection and analysis, decision for publication, or preparation of the manuscript. The authors have no conflicts of interest to disclose. Supplemental Digital Content..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit